CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NanoPhoria is developing an innovative inhalable treatment for heart failure using a unique nanoparticle delivery system. The product, NP-MP1, aims to improve heart function by delivering biologic drugs directly to heart cells, potentially transforming the management of a chronic condition affecting millions.
NanoPhoria bioscience leads the way in the development of groundbreaking inhalable cardiovascular treatments by combining innovative biologic drugs with a unique nanoparticle-mediated delivery platform.We seek EIC support to develop our lead product NP-MP1.
This highly innovative lung-to-heart nano-in-micro peptide formulation has the potential to radically improve the treatment of Heart Failure with reduced Ejection Fraction (HFrEF), a chronic and largely unmet clinical condition affecting mill…
NANOPHORIA SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
